High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma

29Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Urinary LTE4 reflects the whole body production of the cysteinylleukotrienes (LTC4, LTD4 and LTE4) that are established mediators in asthma. The influence of chronic inhaled and oral glucocorticoid treatment on urinary excretion of leukotriene (LT) E4 was investigated in subjects with asthma. Enzyme immunoassay analysis of LTE4 was performed in spot urine samples collected from 40 patients with severe asthma, 25 patients with mild-moderate asthma and 20 non-asthmatic control subjects. Urinary LTE4 was significantly higher in patients with severe asthma (69.7 ± 5.5) as compared to mild-moderate asthma (45.7 ± 3.3 with P < 0.0004) and control (42.5 ± 2.5 with P < 0.0001). Despite chronic systemic treatment with glucocorticoids, chronically severe asthma had presented with higher levels of LTE4 compared to mild-moderate asthma and healthy controls. The findings support previous indications that one important component in asthmatic airway inflammation, the cysteinyl-leukotriene pathway remains relatively unopposed by oral glucocorticoids. © 2003 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Vachier, I., Kumlin, M., Dahlén, S. E., Bousquet, J., Godard, P., & Chanez, P. (2003). High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma. Respiratory Medicine, 97(11), 1225–1229. https://doi.org/10.1016/S0954-6111(03)00253-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free